Literature DB >> 29980529

Neoantigens in Ovarian Cancer: Embarrassment of Riches or Needles in a Haystack?

Iain A McNeish1.   

Abstract

Comprehensive genomic and transcriptomic analysis demonstrate that tumor-infiltrating T lymphocytes that react to mutated neoepitopes could be identified in recurrent ovarian cancer. Two of these T-cell populations reacted against TP53 hotspot missense mutations that are present in a wide variety of malignancies. Clin Cancer Res; 24(22); 5493-5. ©2018 AACR See related article by Deniger et al., p. 5562. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29980529      PMCID： PMC6215482          DOI： 10.1158/1078-0432.CCR-18-1731

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

1.  T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers.

Authors:  Drew C Deniger; Anna Pasetto; Paul F Robbins; Jared J Gartner; Todd D Prickett; Biman C Paria; Parisa Malekzadeh; Li Jia; Rami Yossef; Michelle M Langhan; John R Wunderlich; David N Danforth; Robert P T Somerville; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2018-05-31       Impact factor: 12.531

2.  Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes.

Authors:  H Ikarashi; K Fujita; K Takakuwa; S Kodama; A Tokunaga; T Takahashi; K Tanaka
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

3.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

4.  Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer.

Authors:  Allen W Zhang; Andrew McPherson; Katy Milne; David R Kroeger; Phineas T Hamilton; Alex Miranda; Tyler Funnell; Nicole Little; Camila P E de Souza; Sonya Laan; Stacey LeDoux; Dawn R Cochrane; Jamie L P Lim; Winnie Yang; Andrew Roth; Maia A Smith; Julie Ho; Kane Tse; Thomas Zeng; Inna Shlafman; Michael R Mayo; Richard Moore; Henrik Failmezger; Andreas Heindl; Yi Kan Wang; Ali Bashashati; Diljot S Grewal; Scott D Brown; Daniel Lai; Adrian N C Wan; Cydney B Nielsen; Curtis Huebner; Basile Tessier-Cloutier; Michael S Anglesio; Alexandre Bouchard-Côté; Yinyin Yuan; Wyeth W Wasserman; C Blake Gilks; Anthony N Karnezis; Samuel Aparicio; Jessica N McAlpine; David G Huntsman; Robert A Holt; Brad H Nelson; Sohrab P Shah
Journal:  Cell       Date:  2018-05-10       Impact factor: 41.582

5.  Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.

Authors:  Nikolaos Zacharakis; Harshini Chinnasamy; Mary Black; Hui Xu; Yong-Chen Lu; Zhili Zheng; Anna Pasetto; Michelle Langhan; Thomas Shelton; Todd Prickett; Jared Gartner; Li Jia; Katarzyna Trebska-McGowan; Robert P Somerville; Paul F Robbins; Steven A Rosenberg; Stephanie L Goff; Steven A Feldman
Journal:  Nat Med       Date:  2018-06-04       Impact factor: 53.440
  5 in total
  1 in total

1.  Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer.

Authors:  Tao Dao; Martin G Klatt; Tatyana Korontsvit; Sung Soo Mun; Sean Guzman; Marissa Mattar; Oliver Zivanovic; Chrisann K Kyi; Nicholas D Socci; Roisin E O'Cearbhaill; David A Scheinberg
Journal:  Cancer Immunol Immunother       Date:  2020-10-29       Impact factor: 6.968
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.